Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mission Pharmacal for women and babies

This article was originally published in The Tan Sheet

Executive Summary

The San Antonio-based firm extends its products marketed to women into OTC lotions with the acquisition of Dr. Smith's Diaper Ointment from innovator Esrubar and marketer Beta Dermaceuticals. Mission Pharmacal did not disclose financial terms of the Aug. 31 deal, which also includes Rash-n-All Ointment. The firm already markets CitraNatal prenatal vitamins and Ferralet 90 iron therapy Rx products, and will give samples of Dr. Smith's products to health care providers who buy its prescription drugs and can recommend the ointment to patients, said company President Neill Walsdorf, Jr. According to Information Resources Inc., Dr. Smith's sales were $1.85 million, or 1.82 percent of the category, in the 52 weeks ending Aug. 9, excluding sales at Wal-Mart, club stores and convenience stores. Desitin leads the baby ointment category at $15.7 million, or 15.37 percent, Chicago-based IRI data show. Mission Pharmacal expects to extend Dr. Smith's Diaper Ointment nationwide in 2010 before growing Rash-n-All sales

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel